Alexander Cherkassky is an experienced scientist who worked as platform director at Thermo Fisher Scientific in Waltham, Massachusetts, before joining Fluidigm as senior director in 2018. At Fluidigm, he’s responsible for the development of life science tools to visualize more than 30 cellular parameters at single-cell resolution. Complementing his experience, Alexander Cherkassky holds membership with the American Association of Clinical Chemistry (AACC).
A global organization promoting the health care application of clinical laboratory science, the AACC provides industry leadership in education and advocacy. In terms of advocacy, the organization has sought to enact positive change in the following four areas: children’s health, laboratory regulations, patient access to quality testing, and reimbursement and the changing health care environment.
The AACC is particularly engaged in efforts to improve newborn screening and the interpretation of test results through the development of more efficient pediatric reference intervals. In regard to laboratory regulations, the organization supports public policies with the intent to improve the effectiveness and safety of laboratory-developed tests.
The organization also supports widespread access to quality tests, in addition to efforts to improve uniformity across results. It has been active in ensuring patients have access to COVID-19 tests since the beginning of the pandemic. Finally, the AACC is advocating for increases to the Clinical Laboratory Fee Schedule (CLFS). CLFS rates were recently decreased due to troubles with the roll-out of the Protecting Access to Medicare Act.
Alexander Cherkassky 